AC
IONS icon

Ascend Capital’s Ionis Pharmaceuticals IONS Stock Holding History

Ascend Capital’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-74,100
Closed -$3.27M – 199
2018
Q1 		$3.27M Buy
+74,100
New +$3.76M 0.13% 140
2017
Q4 		– Sell
-134,994
Closed -$6.84M – 232
2017
Q3 		$6.84M Buy
+134,994
New +$7.07M 0.26% 98

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Ascend Capital's IONS Position: Q2 2018 in Review

Ascend Capital sold out of Ionis Pharmaceuticals (IONS) in Q2 2018, closing a stake of 74,100 shares — an estimated $3.27M sold.

Ascend Capital first reported a position in IONS in Q3 2017 and held it in 2 quarters. The position peaked at $6.84M in Q3 2017. 308 funds tracked by Wall St. Rank hold IONS as of Q2 2018.

  • Ascend Capital reported no remaining Ionis Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Ascend Capital sold 74,100 Ionis Pharmaceuticals shares in Q2 2018, an estimated $3.27M.
  • Ascend Capital first reported a position in Ionis Pharmaceuticals in Q3 2017 and held it in 2 quarters.
  • Ascend Capital's Ionis Pharmaceuticals position peaked at $6.84M in Q3 2017.
  • 308 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2018.

Based on Ascend Capital's 13F filing for Q2 2018, filed 13 Aug 2018.